Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Huntsville site will focus on domestic production of small molecule synthetic and peptide medicines, including Lilly’s oral GLP-1,…
New Lancet Phase III Study Shows Proton Therapy Significantly Improves Survival and Reduces Toxicity in Head and Neck Cancers
Ten percent higher 5-year overall survival rates in patients receiving precise proton therapy vs. traditional radiation therapy Patients…
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme’s Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
Partnership unites Illumina’s leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for…
Lin Health Raises $11 Million Series A to Fuel Growth of Virtual Chronic Pain Recovery Platform
Oversubscribed round demonstrates strong investor confidence in Lin Health’s neuroscience-based approach to chronic pain DENVER, Dec. 9, 2025…
Journal of Cardiac Failure December Issue Showcases Innovations in Transplant Care, Digital Therapeutics, and Global Heart Failure Treatment Strategies
WASHINGTON, Dec. 9, 2025 /PRNewswire/ —Â The December issue of the Journal of Cardiac Failure (JCF), now available, offers…
Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival
LAS VEGAS, Dec. 9, 2025 /PRNewswire/ — Avant Technologies, Inc. (OTCQB: AVAI)Â (“Avant” or the “Company”), an emerging biotechnology…
Drug Reduced Need for Blood Transfusions During Hospitalization for Non-Cardiac Surgery
LBA-5:Â A hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery: The TRACTION trial ORLANDO, Fla.,…
FDA Issues Formal Guideline Waiving Clinical Efficacy Studies for Biosimilars, Confirming Professor Niazi’s 15-Year Campaign to Cut Biologic Drug Costs
A Landmark Regulatory Shift Validates Professor Sarfaraz K. Niazi’s Vision to Make Biologics as Affordable as Generics CHICAGO,…
NEUROMARK® Treatment for Chronic Rhinitis Demonstrates Durable 2-Year Clinical Benefits
PARAGON Study Confirms Sustained Efficacy and Safety of NEUROMARK® System in Allergic and Nonallergic Rhinitis Patients GALWAY, Ireland,…
Lilly’s Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer’s disease
Approved for earliest symptomatic stages of disease, demonstrating significant slowing of cognitive and functional decline Only therapy with…
Sleep Aids Market to Hit US$ 118.97 Billion by 2033, Growing at 7.8% CAGR
AUSTIN, Texas and TOKYO, Sept. 19, 2025 /PRNewswire/ — According to DataM Intelligence, the global sleep aids market…
In Vitro Diagnostics (IVD) Quality Control Market worth $2.15 billion by 2030 with 5.5% CAGR
DELRAY BEACH, Fla., Sept. 19, 2025 /PRNewswire/ — The global In Vitro Diagnostics Quality Control Market, valued at…